UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 2423, 2020

NEUROTROPE, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-38045	46-3522381
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

1185 Avenue of the Americas, 3^rd Floor

New York, New York 10036

(Address of principal executive offices, including ZIP code)

(973) 242-0005

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

x¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		NTRP		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company. ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 81.01 ~~Other~~Entry ~~Events~~into a Material Definitive Agreement.

On July 2423, 2020, ~~Petros~~ ~~Pharmaceuticals~~Neurotrope BioScience, Inc. (“Neurotrope BioScience”), a ~~Delaware~~wholly-owned ~~corporation~~consolidated ~~formed~~operating ~~for~~subsidiary ~~the purposes~~ of ~~effecting transactions contemplated by the Merger Agreement~~ ~~(as~~Neurotrope, ~~defined~~Inc. ~~below)~~ (“~~Petros~~Neurotrope”), ~~filed~~executed a ~~registration~~Services ~~statement~~Agreement ~~on Form S-4~~ (~~File No. 333-240064) (~~the “~~Registration Statement~~Agreement”) with Worldwide ~~the~~Clinical UTrials, Inc.S. ~~Securities~~(together ~~and~~with ~~Exchange~~its ~~Commission~~affiliates, (“~~SEC~~WCT”),. ~~which~~The ~~includes~~Agreement arelates ~~preliminary~~to ~~proxy statement~~services offor Neurotrope, ~~Inc.,~~BioScience’s aPhase ~~Nevada~~2 ~~corporation~~clinical ~~(“Neurotrope”)~~study assessing the safety, tolerability and long-term ~~constitutes~~efficacy aof bryostatin ~~preliminary~~in ~~prospectus~~the treatment of ~~Petros~~moderately severe Alzheimer’s disease subjects not receiving memantine treatment (the “Study”).

~~The~~Pursuant ~~Registration~~to ~~Statement~~the terms ~~was~~of ~~filed~~the inAgreement, ~~connection~~WCT ~~with~~will ~~the~~provide ~~previously~~services ~~disclosed~~to ~~Agreement~~enroll ~~and~~approximately ~~Plan~~one ofhundred ~~Merger~~ (~~the~~100) ~~“Original~~Study ~~Merger~~subjects. ~~Agreement”),~~Neurotrope and Neurotrope ~~dated~~BioScience asexpect ofthat ~~May~~the ~~17,~~first ~~2020, by~~Study ~~and~~site ~~among~~will ~~Petros,~~be ~~Neurotrope,~~initiated PMduring ~~Merger~~the ~~Sub~~third 1,quarter ~~LLC,~~of a2020. ~~Delaware~~The ~~limited~~total ~~liability~~estimated ~~company~~budget ~~and~~for athe ~~wholly~~services, including pass-~~owned~~through ~~subsidiary~~costs, ofis ~~Petros~~approximately ~~(“Merger~~$9.8 ~~Sub~~million. ~~1”),~~As PNpreviously ~~Merger~~disclosed ~~Sub~~on 2January 22, ~~Inc.~~2020, aNeurotrope ~~Delaware~~has ~~corporation~~received ~~and~~ a ~~wholly-owned subsidiary~~$2.7 ofmillion ~~Petros~~award ~~(“Merger~~from ~~Sub~~the ~~2”),~~National ~~and~~Institutes ~~Metuchen~~of ~~Pharmaceuticals LLC~~Health, awhich ~~Delaware~~award ~~limited~~will ~~liability~~be ~~company~~used ~~(“Metuchen”)~~to support the Study, as ~~amended~~resulting byin ~~the~~an ~~First~~estimated ~~Amendment~~net tobudgeted cost of the ~~Original~~Study ~~Merger~~to ~~Agreement~~Neurotrope ~~(the~~of ~~“Merger~~$7.1 ~~Agreement~~million. ~~Amendment”~~In ~~and,~~connection ~~together~~ with ~~the~~their ~~Original~~entry ~~Merger~~into ~~Agreement,~~ the ~~“Merger~~ Agreement”), ~~dated~~the parties asagreed ofthat ~~July~~WCT ~~23,~~would ~~2020,~~invoice ~~providing~~Neurotrope BioScience for ~~(1)~~ the ~~merger~~ offollowing ~~Merger~~advance ~~Sub~~payments: 1(i) ~~with~~services ~~and~~fees ~~into~~of ~~Metuchen~~approximately $490,000; ~~with~~(ii) ~~Metuchen surviving as a wholly~~pass-~~owned~~through ~~subsidiary~~expenses of ~~Petros~~approximately ~~(the~~$140,000; ~~“Metuchen Merger”)~~ and (2iii) ~~the~~ ~~merger~~investigator/institute fees of ~~Merger~~approximately ~~Sub~~$310,000, which 2in ~~with~~each ~~and~~case ~~into~~will ~~Neurotrope,~~be ~~with~~due ~~Neurotrope~~within ~~surviving~~ten as(10) adays ~~wholly-owned~~of ~~subsidiary~~ Neurotrope BioScience’s receipt of ~~Petros~~such ~~(the~~invoice. “Neurotrope ~~Merger”~~BioScience may ~~and,~~terminate ~~together~~the ~~with~~Agreement ~~the~~without ~~Metuchen~~cause ~~Merger,~~upon ~~the~~sixty ~~“Mergers”~~(60) days prior written notice.

~~The~~Unless ~~Registration~~earlier ~~Statement~~terminated under ~~has~~the ~~not~~provisions ~~yet~~of the Agreement, the Agreement will expire upon WCT’s completed performance of the services thereunder ~~been~~(including ~~declared~~delivery ~~effective~~of byall the ~~SEC.~~deliverables) ~~The~~and ~~Registration~~WCT’s ~~Statement~~receipt isof ~~available~~all onpayments from Neurotrope BioScience that are due under the ~~SEC~~Agreement. In addition to Neurotrope BioScience’s ~~EDGAR~~termination ~~system~~right described above, Neurotrope BioScience may terminate the Agreement immediately due to patient safety. Further, under the Agreement, either Neurotrope BioScience or WCT may terminate the Agreement if the other party materially breaches the Agreement and fails to cure such breach. Additionally, either Neurotrope BioScience or WCT may beterminate ~~accessed~~the Agreement upon notice to the other party if the other party is adjudicated insolvent or petitions atfor ~~www~~relief under any insolvency, re-organization, receivership, liquidation, compromise, or any moratorium statute.~~sec.gov.~~

~~Forward~~The foregoing description of the Agreement is qualified in its entirety by reference to the Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-~~Looking~~K ~~Statements~~and is incorporated in its entirety into this Item 1.01 by reference.

~~This~~Item communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Neurotrope, Metuchen, the proposed transactions and other matters9. ~~These~~01 ~~statements~~Financial may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Neurotrope, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements ~~that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs~~ and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the conditions to the closing of the transactions are not satisfied, including the failure to obtain stockholder approval for the transactions in a timely manner or at all; uncertainties as to the timing of the consummation of the Mergers and the spin-off of Neurotrope’s wholly-owned subsidiary, Neurotrope Bioscience, Inc., and the ability of each of Petros, Neurotrope and Metuchen to consummate the transactions; risks related to Petros’ initial listing on The Nasdaq Capital Market at the closing of the proposed transaction; risks related to Neurotrope’s ability to correctly estimate its operating expenses and its expenses associated with the transaction; the ability of Neurotrope or Metuchen to protect their respective intellectual property rights; competitive responses to the transaction; unexpected costs, charges or expenses resulting from the transaction; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Neurotrope’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. Neurotrope can give no assurance that the conditions to the transaction will be satisfied. Except as required by applicable law, Neurotrope undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.Exhibits

NoThe ~~Offer~~following orexhibit ~~Solicitation~~is filed herewith:

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (~~including without limitation, facsimile transmission, telephone and the internet~~d) ~~of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction~~Exhibits.

Important Information About the Business Combination and Where to Find It

Exhibit No.		Description
10.1*		Services Agreement, by and between Worldwide Clinical Trials, Inc. and Neurotrope BioScience Inc., dated as of July 23, 2020.

In* ~~connection~~Confidential ~~with the~~treatment ~~proposed transaction among Petros, Neurotrope and Metuchen, Petros~~ has ~~filed~~been arequested ~~Registration~~for ~~Statement~~certain onportions ~~Form S-4, which includes a preliminary proxy statement~~ of ~~Neurotrope.~~this ~~Petros intends to file additional relevant materials with the SEC~~exhibit. ~~NEUROTROPE URGES~~ ~~INVESTORS~~The ~~AND~~unredacted ~~STOCKHOLDERS~~document TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT PETROS, NEUROTROPE, METUCHEN, THE PROPOSED TRANSACTIONS AND RELATED MATTERS. Investors and shareholders will be ~~able~~provided tosupplementally obtain free copies of the proxy statement, prospectus and other documents filed by Petros and Neurotrope with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors and shareholders will be able to ~~obtain free copies of~~ the ~~proxy~~Securities ~~statement, prospectus~~ and ~~other~~Exchange ~~documents~~Commission ~~filed~~upon by Petros and Neurotrope with the SEC by contacting Investor Relations by mail at Neurotrope, Inc., Attn: Investor Relations, 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036. Investors and stockholders are urged to read the proxy statement, prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.request

~~Participants in the Solicitation~~SIGNATURES

~~Petros,~~Pursuant ~~Neurotrope and Metuchen, and each of their respective directors and executive officers and certain of their other members of management and employees, may be deemed~~ to ~~be participants in~~ the ~~solicitation~~ requirements of ~~proxies in connection with~~ the ~~proposed~~Securities ~~transaction.~~Exchange ~~Information about~~Act ~~Neurotrope’s~~of ~~directors and executive officers is included in Neurotrope’s Annual Report on Form 10-K for the year ended December 31~~1934, ~~2019, filed with~~ the ~~SEC~~Registrant onhas ~~March 13,~~duly ~~2020. Additional~~caused ~~information~~this ~~regarding~~report ~~these persons~~to ~~and~~be ~~their~~signed ~~interests in the transaction is included in the Registration Statement~~ on ~~Form~~its ~~S-4~~behalf ~~filed~~ by ~~Petros.~~the ~~These documents~~undersigned ~~can~~hereunto beduly ~~obtained free of charge from the sources indicated above~~authorized.

SIGNATURES

	NEUROTROPE, INC.

Dated: July 29, 2020	By:	/s/ Robert Weinstein
		Name: Robert Weinstein
		Title: Chief Financial Officer, Executive Vice President, Secretary and Treasurer

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUROTROPE, INC.
Dated: July 24, 2020	By:	/s/ Robert Weinstein
		Name: Robert Weinstein
		Title: Chief Financial Officer, Executive Vice President, Secretary and Treasurer

Filing Compare · Neurotrope, Inc.